Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of “Hold” by Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $9.40.

A number of brokerages have commented on RXRX. Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Jefferies Financial Group decreased their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,353,265.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total value of $109,800.00. Following the completion of the transaction, the chief financial officer now directly owns 1,292,218 shares in the company, valued at $9,459,035.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total value of $48,780.00. Following the completion of the sale, the chief operating officer now owns 535,457 shares in the company, valued at approximately $4,353,265.41. The disclosure for this sale can be found here. Over the last quarter, insiders sold 225,682 shares of company stock valued at $1,590,044. 15.75% of the stock is owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of RXRX. Benjamin F. Edwards & Company Inc. acquired a new position in Recursion Pharmaceuticals in the first quarter valued at about $26,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. Amalgamated Bank increased its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Midwest Financial Group LLC purchased a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Xponance Inc. acquired a new position in Recursion Pharmaceuticals during the second quarter worth $98,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $6.98 on Friday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -4.36 and a beta of 0.82. The stock has a 50-day moving average of $7.03 and a 200 day moving average of $8.22. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a twelve month low of $4.97 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The company had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. Recursion Pharmaceuticals’s revenue was up 30.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.38) EPS. Sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.58 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.